相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Merryn Voysey et al.
LANCET (2021)
An Observational Laboratory-Based Assessment of SARS-CoV-2 Molecular Diagnostics in Benin, Western Africa
Anna-Lena Sander et al.
MSPHERE (2021)
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Denis Y. Logunov et al.
LANCET (2021)
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Yanjun Zhang et al.
LANCET INFECTIOUS DISEASES (2021)
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant
Elisabeth Mahase
BMJ-BRITISH MEDICAL JOURNAL (2021)
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
S. A. Madhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
V. Shinde et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Chang Liu et al.
CELL (2021)
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Delphine Planas et al.
NATURE (2021)
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
Alejandro Jara et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants
Pinja Jalkanen et al.
NATURE COMMUNICATIONS (2021)
Development of an inactivated vaccine candidate for SARS-CoV-2
Qiang Gao et al.
SCIENCE (2020)
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2
Hui Wang et al.
CELL (2020)
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes Interim Analysis of 2 Randomized Clinical Trials
Shengli Xia et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
A minimal common outcome measure set for COVID-19 clinical research
J. C. Marshall et al.
LANCET INFECTIOUS DISEASES (2020)
Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial
Ricardo Palacios et al.
TRIALS (2020)
Effectiveness of EV-A71 vaccination in prevention of paediatric hand, foot, and mouth disease associated with EV-A71 virus infection requiring hospitalisation in Henan, China, 2017-18: a test-negative case-control study
Yu Li et al.
LANCET CHILD & ADOLESCENT HEALTH (2019)
Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010-2011: a population-based test-negative case-control study
Ivan Martinez-Baz et al.
BMC PUBLIC HEALTH (2013)
Effectiveness of seasonal 2008-2009, 2009-2010 and pandemic vaccines, to prevent influenza hospitalizations during the autumn 2009 influenza pandemic wave in Castellon, Spain. A test-negative, hospital-based, case-control study
Joan Puig-Barbera et al.
VACCINE (2010)